Sperm, Exposure and Endocrine Disruptors (SEED)
perjantai 10. heinäkuuta 2026 päivittänyt: Jenna Hua, Million Marker Wellness, Inc.
Endocrine Disruptors and Men's Reproductive Health: A Randomized Behavioral Intervention to Increase Environmental Health Literacy and Reduce Exposures Among Men With Low Semen Quality
The proposed research aims to 1) measure male participants' urinary levels of EDCs and sperm quality before and after report-back and EDC reduction intervention and assess changes, 2) assess the extent to which MM's program (testing, curriculum, and report-back) alters participant environmental health literacy (EHL), readiness to change (RtC), and product/lifestyle choices, and 3) test the feasibility and acceptability of MM's program to male participants.
The primary study subjects are adult men of reproductive age.
The study aims to have 60 participants complete the study.
Tutkimuksen yleiskatsaus
Tila
Ei vielä rekrytointia
Interventio / Hoito
Yksityiskohtainen kuvaus
The SEED study hypothesizes that our report-back and intervention program will increase environmental health literacy and EDC-reduction behavior, reduce urinary EDCs, and improve semen quality in a sample of US men with low semen quality.
And the intervention program will have a larger effect than report-back only.
The study will consist of three Aims: 1) Measure male participants' urinary levels of EDCs and semen quality before and after report-back and EDC reduction intervention and assess change.
60 men, with previously established low semen quality, will be recruited from Fellow Health customers (a direct-to-consumer semen testing company).
All participants' EDC exposures will be assessed via the MM test kit and receive personalized report-back.
Subsequently, in a randomized-controlled trial, 30 participants (i.e. the intervention group) will engage in an 8-session online EDC environmental health literacy curriculum, as well as an online forum and coaching sessions, aimed to increase environmental health literacy and exposure reduction behavior.
Thirty participants (i.e. the control group) will receive the report-back only.
After completion of the curriculum, participants will retest urinary EDCs.
Semen quality at these two time points will also be collected.
Differences between the intervention and control groups will be assessed.
2) Assess the extent to which MM's program (testing, curriculum, and report-back) alters participant environmental health literacy, readiness to change, and product/lifestyle choices.
Measures of environmental health literacy, willingness/readiness to reduce exposure, exposure reduction behavior, and sources of exposure will be assessed pre- and post-testing/intervention via previously validated surveys, including environmental health literacy and readiness to change (i.e.
ready to reduce exposure), and lifestyle audits (including product use, diet, and lifestyle factors).
Differences between the intervention and control groups will be assessed.
3) Test the feasibility and acceptability of MM's program to male participants.
The usability, feasibility, and overall acceptability of the MM intervention program (i.e.
testing, report-back, curriculum, coaching sessions) will be assessed in participants via the System Usability Score and other participant satisfaction questions.
Further, focus groups and key informant interviews will be conducted in a subset of participants following the study to gather both qualitative and quantitative information to assess and improve the MM program.
Opintotyyppi
Interventio
Ilmoittautuminen (Arvioitu)
100
Vaihe
- Ei sovellettavissa
Yhteystiedot ja paikat
Tässä osiossa on tutkimuksen suorittajien yhteystiedot ja tiedot siitä, missä tämä tutkimus suoritetaan.
Opiskeluyhteys
- Nimi: Jenna Hua, MPH, PhD
- Puhelinnumero: 510-305-5690
- Sähköposti: Jenna@millionmarker.com
Tutki yhteystietojen varmuuskopiointi
- Nimi: Chris Ribbens
- Sähköposti: Chris@millionmarker.com
Opiskelupaikat
-
-
California
-
Berkeley, California, Yhdysvallat, 94704
- Million Marker Wellness Inc.
-
-
Osallistumiskriteerit
Tutkijat etsivät ihmisiä, jotka sopivat tiettyyn kuvaukseen, jota kutsutaan kelpoisuuskriteereiksi. Joitakin esimerkkejä näistä kriteereistä ovat henkilön yleinen terveydentila tai aiemmat hoidot.
Kelpoisuusvaatimukset
Opintokelpoiset iät
- Aikuinen
- Vanhempi Aikuinen
Hyväksyy terveitä vapaaehtoisia
Ei
Kuvaus
Inclusion Criteria:
- Men,
- Reproductive Age,
- Good Health,
- Non-Smoker
- English-Speaking
- No Occupational/Medical Risks
- not using steroids or TRT/hormone replacement supplements
- low sperm count=total motile count below 20 million/ml
- tested by Fellow in the last 3 months
Exclusion Criteria:
- Women
- Non-Reproductive Age
- Poor Health
- Smoker
- Non-English Speaking
- Occupational/Medical Risks
- using steroids or TRT/hormone replacement supplements
- total motile count over 20 mil/ml, tested by Fellow over 3 months ago
Opintosuunnitelma
Tässä osiossa on tietoja tutkimussuunnitelmasta, mukaan lukien kuinka tutkimus on suunniteltu ja mitä tutkimuksella mitataan.
Miten tutkimus on suunniteltu?
Suunnittelun yksityiskohdat
- Ensisijainen käyttötarkoitus: Hoito
- Jako: Satunnaistettu
- Inventiomalli: Rinnakkaistehtävä
- Naamiointi: Yksittäinen
Aseet ja interventiot
Osallistujaryhmä / Arm |
Interventio / Hoito |
|---|---|
|
Kokeellinen: Education Intervention
Study participants receive lifestyle audit and educational intervention program in addition to urine and sperm testing.
|
Participants receive a 14 module intervention program about endocrine disrupting chemicals and reducing exposures.
Participants must complete at least 8 modules over the course of 8 weeks.
|
|
Ei väliintuloa: Control
Study participants receive urine and sperm testing only.
|
Mitä tutkimuksessa mitataan?
Ensisijaiset tulostoimenpiteet
Tulosmittaus |
Toimenpiteen kuvaus |
Aikaikkuna |
|---|---|---|
|
Change in Environmental Health Literacy
Aikaikkuna: 12-weeks
|
This surveys assesses EDC-specific environmental health literacy, based on questions in a 5-point Likert scale from 1 (strongly agree) to 5 (strongly disagree) or 1 (never) to 5 (always).
Responses will be reverse coded during analysis as needed so that higher numbers reflect positive outcomes (higher EDC-EHL).
|
12-weeks
|
|
Change in Sperm Count
Aikaikkuna: 12 Weeks
|
Changes measured from Fellow Sperm Test- total motile count at the baseline and post intervention.
|
12 Weeks
|
|
Change in Readiness to Change
Aikaikkuna: 12 weeks
|
The Readiness to Change question asks participants to choose the response (sentence) that most accurately describes their current efforts and interest in limiting their exposure to harmful chemicals.
Responses will be coded from 1 to 5 with 5 reflecting greater readiness to reduce risky behaviors.
|
12 weeks
|
|
Change in Metabolites
Aikaikkuna: 12 weeks
|
Urinary EDC metabolites include bisphenols, phthalates, parabens and oxybenzone.
|
12 weeks
|
Toissijaiset tulostoimenpiteet
Tulosmittaus |
Toimenpiteen kuvaus |
Aikaikkuna |
|---|---|---|
|
Change in Sexual Satisfaction (From the International Index of Erectile Function (IIEF) Survey)
Aikaikkuna: 12-weeks
|
Measured pre and post intervention to Likert style questions from 1 to 5 on overall self reported sexual satisfaction with higher score indicating more satisfied.
Two questions taken from validated survey questions from the international index of erectile function survey including "how satisfied have you been with your overall sex life?" https://www.browardurologycenter.com/pdf/International-Index-of-Erectile-Function-IIEF-Questionnaire.pdf
|
12-weeks
|
|
Change in Sexual Health Inventory (SHIM)
Aikaikkuna: 12-weeks
|
Validated survey measured pre and post intervention Add the numbers corresponding to questions 1-5. TOTAL: The Sexual Health Inventory for Men further classifies ED severity with the following breakpoints: 1-7 Severe ED 8-11 Moderate ED 12-16 Mild to Moderate ED 17-21 Mild ED |
12-weeks
|
|
Product Usage
Aikaikkuna: 12 Weeks
|
Changes in # of reported product usage including personal care, household, and hair products with more products being worse and less products being better.
|
12 Weeks
|
|
System Usability Score (SUS)
Aikaikkuna: 12-weeks
|
SUS is a validated survey measuring the usability of the intervention program at the end of intervention.
The score is calculated from 0 to 100 with the greater the score indicating better perceived usability.
Scores 60 and greater are considered acceptable.
|
12-weeks
|
|
Change in Stress
Aikaikkuna: 12-weeks
|
Change in stress (from validated survey Perceived Stress Scale (PSS-4)).
Summarize 4 questions for a score of 0-16.
Higher score equals greater stress.
|
12-weeks
|
|
Intervention Completion
Aikaikkuna: At the end of intervention (12-weeks)
|
Number of total modules completed/requirements completed
|
At the end of intervention (12-weeks)
|
|
Change in General Health
Aikaikkuna: 12 weeks
|
Change in self rated general health ( Behavioral Risk Factor Surveillance System (BRFSS)) "In general my health is" from very good to very bad (coded 1 to 5, 5 being very good).
These variables are exploratory and may or may not be included in final analysis.
|
12 weeks
|
|
Change in Sleep
Aikaikkuna: 12 weeks
|
Change in sleep (BRFSS- Behavioral Risk Factor Surveillance System), including self reported hours of sleep and sleep quality from very good to very bad(coded 1 to 5, 5 being very good).
These variables are exploratory and may or may not be included in final analysis.
|
12 weeks
|
|
Change in Physical Activity
Aikaikkuna: 12 Weeks
|
Change in physical activity (validated survey International Physical Activity Questionnaire (IPAQ)) using calculated MET (Metabolic Equivalent of Task) scores to classify into low, moderate or high physical activity (higher being better). MET score = (how many days × how many minutes × how hard the activity is), added across all activity types." Walking= 3.3 METs Moderate activity=4.0 METs Vigorous activity=8.0 METs These variables are exploratory and may or may not be included in final analysis. |
12 Weeks
|
Yhteistyökumppanit ja tutkijat
Täältä löydät tähän tutkimukseen osallistuvat ihmiset ja organisaatiot.
Sponsori
Tutkijat
- Opintojohtaja: Johanna Rochester, PhD, Million Marker Wellness
Julkaisuja ja hyödyllisiä linkkejä
Tutkimusta koskevien tietojen syöttämisestä vastaava henkilö toimittaa nämä julkaisut vapaaehtoisesti. Nämä voivat koskea mitä tahansa tutkimukseen liittyvää.
Yleiset julkaisut
- Rochester JR. Bisphenol A and human health: a review of the literature. Reprod Toxicol. 2013 Dec;42:132-55. doi: 10.1016/j.reprotox.2013.08.008. Epub 2013 Aug 30.
- Trasande L, Zoeller RT, Hass U, Kortenkamp A, Grandjean P, Myers JP, DiGangi J, Hunt PM, Rudel R, Sathyanarayana S, Bellanger M, Hauser R, Legler J, Skakkebaek NE, Heindel JJ. Burden of disease and costs of exposure to endocrine disrupting chemicals in the European Union: an updated analysis. Andrology. 2016 Jul;4(4):565-72. doi: 10.1111/andr.12178. Epub 2016 Mar 22.
- Harley KG, Kogut K, Madrigal DS, Cardenas M, Vera IA, Meza-Alfaro G, She J, Gavin Q, Zahedi R, Bradman A, Eskenazi B, Parra KL. Reducing Phthalate, Paraben, and Phenol Exposure from Personal Care Products in Adolescent Girls: Findings from the HERMOSA Intervention Study. Environ Health Perspect. 2016 Oct;124(10):1600-1607. doi: 10.1289/ehp.1510514. Epub 2016 Mar 7.
- Attina TM, Hauser R, Sathyanarayana S, Hunt PA, Bourguignon JP, Myers JP, DiGangi J, Zoeller RT, Trasande L. Exposure to endocrine-disrupting chemicals in the USA: a population-based disease burden and cost analysis. Lancet Diabetes Endocrinol. 2016 Dec;4(12):996-1003. doi: 10.1016/S2213-8587(16)30275-3. Epub 2016 Oct 17.
- Rochester JR, Kwiatkowski CF, Neveux I, Dabe S, Hatcher KM, Lathrop MK, Daza EJ, Eskenazi B, Grzymski JJ, Hua J. A Personalized Intervention to Increase Environmental Health Literacy and Readiness to Change in a Northern Nevada Population: Effects of Environmental Chemical Exposure Report-Back. Int J Environ Res Public Health. 2024 Jul 11;21(7):905. doi: 10.3390/ijerph21070905.
- Finn S, O'Fallon L. The Emergence of Environmental Health Literacy-From Its Roots to Its Future Potential. Environ Health Perspect. 2017 Apr;125(4):495-501. doi: 10.1289/ehp.1409337. Epub 2015 Jun 30.
- Hauser R, Skakkebaek NE, Hass U, Toppari J, Juul A, Andersson AM, Kortenkamp A, Heindel JJ, Trasande L. Male reproductive disorders, diseases, and costs of exposure to endocrine-disrupting chemicals in the European Union. J Clin Endocrinol Metab. 2015 Apr;100(4):1267-77. doi: 10.1210/jc.2014-4325. Epub 2015 Mar 5.
- Green MP, Harvey AJ, Finger BJ, Tarulli GA. Endocrine disrupting chemicals: Impacts on human fertility and fecundity during the peri-conception period. Environ Res. 2021 Mar;194:110694. doi: 10.1016/j.envres.2020.110694. Epub 2020 Dec 30.
- Gore AC, Chappell VA, Fenton SE, Flaws JA, Nadal A, Prins GS, Toppari J, Zoeller RT. EDC-2: The Endocrine Society's Second Scientific Statement on Endocrine-Disrupting Chemicals. Endocr Rev. 2015 Dec;36(6):E1-E150. doi: 10.1210/er.2015-1010. Epub 2015 Nov 6.
- Sharma A, Mollier J, Brocklesby RWK, Caves C, Jayasena CN, Minhas S. Endocrine-disrupting chemicals and male reproductive health. Reprod Med Biol. 2020 Apr 14;19(3):243-253. doi: 10.1002/rmb2.12326. eCollection 2020 Jul.
- Rochester JR, Kwiatkowski CF, Lathrop MK, Neveux I, Daza EJ, Grzymski J, Hua J. Reducing Exposures to Endocrine Disruptors (REED) study, a personalized at-home intervention program to reduce exposure to endocrine disrupting chemicals among a child-bearing age cohort: study protocol for a randomized controlled trial. Trials. 2024 Nov 25;25(1):793. doi: 10.1186/s13063-024-08627-3.
- Cannarella R, Gul M, Rambhatla A, Agarwal A. Temporal decline of sperm concentration: role of endocrine disruptors. Endocrine. 2023 Jan;79(1):1-16. doi: 10.1007/s12020-022-03136-2. Epub 2022 Oct 4.
- Giulivo M, Lopez de Alda M, Capri E, Barcelo D. Human exposure to endocrine disrupting compounds: Their role in reproductive systems, metabolic syndrome and breast cancer. A review. Environ Res. 2016 Nov;151:251-264. doi: 10.1016/j.envres.2016.07.011. Epub 2016 Aug 7.
Hyödyllisiä linkkejä
Opintojen ennätyspäivät
Nämä päivämäärät seuraavat ClinicalTrials.gov-sivustolle lähetettyjen tutkimustietueiden ja yhteenvetojen edistymistä. National Library of Medicine (NLM) tarkistaa tutkimustiedot ja raportoidut tulokset varmistaakseen, että ne täyttävät tietyt laadunvalvontastandardit, ennen kuin ne julkaistaan julkisella verkkosivustolla.
Opi tärkeimmät päivämäärät
Opiskelun aloitus (Arvioitu)
Maanantai 15. kesäkuuta 2026
Ensisijainen valmistuminen (Arvioitu)
Tiistai 1. joulukuuta 2026
Opintojen valmistuminen (Arvioitu)
Maanantai 1. maaliskuuta 2027
Opintoihin ilmoittautumispäivät
Ensimmäinen lähetetty
Perjantai 26. kesäkuuta 2026
Ensimmäinen toimitettu, joka täytti QC-kriteerit
Perjantai 10. heinäkuuta 2026
Ensimmäinen Lähetetty (Todellinen)
Tiistai 14. heinäkuuta 2026
Tutkimustietojen päivitykset
Viimeisin päivitys julkaistu (Todellinen)
Tiistai 14. heinäkuuta 2026
Viimeisin lähetetty päivitys, joka täytti QC-kriteerit
Perjantai 10. heinäkuuta 2026
Viimeksi vahvistettu
Keskiviikko 1. heinäkuuta 2026
Lisää tietoa
Tähän tutkimukseen liittyvät termit
Avainsanat
Muita asiaankuuluvia MeSH-ehtoja
Muut tutkimustunnusnumerot
- 1R43ES036911
Yksittäisten osallistujien tietojen suunnitelma (IPD)
Aiotko jakaa yksittäisten osallistujien tietoja (IPD)?
JOO
IPD-suunnitelman kuvaus
Million Marker will disseminate research results and findings to the scientific community through presentations at scientific meetings and conferences and publications in academic journals, as well as through the mass media and online postings.
The Principal Investigator of this study will make data and associated documentation/metadata available to external researchers under a data-sharing agreement in which a specific commitment is made to use the data for research purposes only, to not provide the data to a third party or distribute it in any form, and to properly acknowledge the source of funding for the collection of the data and the researchers involved in this study.
IPD-jaon aikakehys
Starting six months after publication
IPD-jaon käyttöoikeuskriteerit
Researchers must submit an acceptable research plan (goals of the proposed research, the specific hypotheses to be examined, justification for research and methods), be affiliated with a recognized research institution, have demonstrated expertise in the area of the proposed research project, and receive independent approval from their governing institutional review board.
Data will be available for use only to answer the specific question(s) indicated in the research plan.
The researchers must provide a list of variable names and an outline of how research findings will be disseminated; and will be asked to sign a data-sharing agreement that commits to: 1) not attempt to identify any individual participant, 2) secure the data using appropriate software technology, 3) and destroy or return all data once analyses are complete.
All final datasets will be de-identified.
Final authorship on manuscripts will require review and approval by the Principal Investigators of this study.
IPD-jakamista tukeva tietotyyppi
- STUDY_PROTOCOL
- MAHLA
- ICF
Lääke- ja laitetiedot, tutkimusasiakirjat
Tutkii yhdysvaltalaista FDA sääntelemää lääkevalmistetta
Ei
Tutkii yhdysvaltalaista FDA sääntelemää laitetuotetta
Ei
Nämä tiedot haettiin suoraan verkkosivustolta clinicaltrials.gov ilman muutoksia. Jos sinulla on pyyntöjä muuttaa, poistaa tai päivittää tutkimustietojasi, ota yhteyttä register@clinicaltrials.gov. Heti kun muutos on otettu käyttöön osoitteessa clinicaltrials.gov, se päivitetään automaattisesti myös verkkosivustollemme .